Champions Oncology (NASDAQ:CSBR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Champions Oncology (NASDAQ:CSBR) announced its earnings results on Monday. The biotechnology company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.04, Fidelity Earnings reports. Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%. The company had revenue of $7.63 million during the quarter, compared to the consensus estimate of $7.83 million.

Shares of Champions Oncology stock opened at $7.18 on Thursday. The business’s fifty day simple moving average is $6.02 and its 200 day simple moving average is $6.64. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 2.06. Champions Oncology has a 12 month low of $4.98 and a 12 month high of $12.80. The firm has a market capitalization of $78.90 million, a P/E ratio of 718.00 and a beta of 1.20.

Several research firms recently weighed in on CSBR. Roth Capital started coverage on shares of Champions Oncology in a report on Friday, September 20th. They set a “buy” rating and a $9.25 price target on the stock. Zacks Investment Research raised shares of Champions Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, September 24th. ValuEngine lowered shares of Champions Oncology from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Benchmark assumed coverage on shares of Champions Oncology in a research report on Wednesday, November 27th. They set a “buy” rating and a $11.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $12.42.

Champions Oncology Company Profile

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Read More: Guidelines for Successful Channel Trading

Earnings History for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with's FREE daily email newsletter.